A short-term oral corticosteroid for refractory lumbar spinal stenosis: a double-blinded randomized placebo-controlled clinical trial

• Published in: International journal of rehabilitation research Vol. 43; no. 4; pp. 342 - 346
• Main Authors: Akbari Aghdam, Hossein, Andalib, Ali, Asadiyan Ardakani, Hossein, Telloo, Mahshid, Sheikhbahaei, Erfan
• Format: Journal Article
• Language: English
• Published: England Wolters Kluwer Health, Inc. All rights reserved 01-12-2020; Copyright Wolters Kluwer Health, Inc. All rights reserved; Lippincott Williams & Wilkins Ovid Technologies
• Subjects: Administration, Oral; Clinical trials; Control Groups; Disability Evaluation; Double-Blind Method; Female; Glucocorticoids - therapeutic use; Humans; Low Back Pain - drug therapy; Low Back Pain - physiopathology; Lumbar Vertebrae - physiopathology; Male; Middle Aged; Pain; Pain Measurement; Patients; Prednisolone - therapeutic use; Rating Scales; Spinal stenosis; Spinal Stenosis - drug therapy; Spinal Stenosis - physiopathology; Walking - physiology
• ISSN: 0342-5282; 1473-5660
• DOI: 10.1097/MRR.0000000000000432

Although epidural corticosteroids have been evaluated for the lumbar spinal stenosis (LSS) as an alternative treatment, oral corticosteroids have not been considered as a possible option for the patients with constant pain who have resistant against routine treatments. Therefore, this study aimed to investigate the efficacy of the short-term, low-dose oral prednisolone for refractory LSS. In this double-blinded randomized placebo-controlled clinical trial, 100 participants with the refractory LSS were selected from the out-patient clinics; however, 7 of them excluded before randomization. The patients were randomly allocated into two groups with a 1:1 ratiothe intervention group that received 10 mg prednisolone per day for 1 week and the control group that received the exact placebo. The patients’ severity of pain in terms of the numerical rating scale, ability to walk in meters, and Oswestry Disability Index (ODI) were assessed and then compared to the baseline after 2 months. The baseline variables were NS between these two groups. At the 2-month follow-up, the ability to walk in meters has increased and the severity of pain and ODI have decreased in both groups. Notably, except for the walking distance, none of the differences were statistically significant. Except for the significant change in walking distance between the groups, no other significant difference was observed in any variables when comparing the delta of each variable (after–before). One-week treatment with daily 10 mg oral prednisolone was not effective on the patients with refractory LSS in the short-term follow-up.